 | |
| Clinical data | |
|---|---|
| Trade names | Vasocon-a |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | Topical (nasal,eye drops) |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.001.904 |
| Chemical and physical data | |
| Formula | C17H19N3 |
| Molar mass | 265.360 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Antazoline is a 1st generationantihistamine withanticholinergic properties used to relievenasal congestion and ineye drops, usually in combination withnaphazoline, to relieve the symptoms ofallergicconjunctivitis.[2] To treat allergic conjunctivitis, antazoline can be combined in a solution withtetryzoline.[3] The drug is aHistamine H1 receptor antagonist:[4] selectively binding to but not activating the receptor, thereby blocking the actions of endogenoushistamine and subsequently leading to the temporary relief of the negative symptoms brought on by histamine.
A 2015 study on people aged 65 years of age or older linked the development ofAlzheimer's disease and other forms of dementia to the "higher cumulative" use of first-generation antihistamines, due to theiranticholinergic properties.[5]
 | Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byexpanding it. |
